PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1629 participants.
Also called NCT03168776
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 1,629 participants
- Registry
-
NCT03168776
-
- Other papers using this trial's data
- Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Canada, Japan, Netherlands, Spain, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03168776. Randomized; single masking; primary purpose treatment. Start 2017-10-13 (actual); primary completion 2020-10-01 (actual). Results posted on 2026-01-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease
- Condition
- Coronary Artery Disease
- Intervention (Device)
- BuMA Supreme DES
- Intervention (Device)
- Xience or Promus DES
- Lead sponsor
- Sino Medical Sciences Technology Inc.
- Collaborator
- Nova Vascular LLC
Record details
- Record id
cardio:ct-nct03168776- Content hash
ccd2c026f88ca5e4217781ac1ad701e274125f0e078cc7f8c8b59eaad80a1d5a